Alterity Therapeutics Ltd (ASX:ATH) Share Price

Company Profile

Business description
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson’s disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
Contact
350 Collins Street
Suite 4, Level 14
MelbourneVIC3000
AUS
T: +61 393494906
E: [email protected]
https://www.alteritytherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
9

Recommended

Big 4 bank maintains Fair Value, Short-term earnings not material enough to shift valuation for key player

Nathan Zaia | 11 August 2026

Shares in Aussie listed healthcare name undervalued post earnings.

Lochlan Halloway, CFA | 11 August 2026

Wide moat share continues to grow despite a challenging residential construction market.

Esther Holloway | 10 August 2026

Index	Last price	Change	% Change
All Ordinaries	9,404.70	0.80	-0.01%
CAC 40	8,690.17	24.77	-0.28%
DAX 40	26,421.50	30.08	0.11%
Dow JONES (US)	53,791.85	184.13	-0.34%
FTSE 100	10,828.96	15.23	-0.14%
HKSE	25,440.17	212.65	-0.83%
NASDAQ	26,445.45	159.91	-0.60%
Nikkei 225	67,524.06	553.84	0.83%
NZX 50 Index	13,737.66	123.00	-0.89%
S&P 500	7,728.20	24.91	-0.32%
S&P/ASX 200	9,209.40	2.20	-0.02%
SSE Composite Index	3,946.68	12.58	0.32%